INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation

Omeros disclosed that the EMA CHMP adopted a negative opinion on its marketing authorization application for narsoplimab in TA-TMA after an oral explanation meeting. The stock dropped $2.05 per share (-19.12%) to close at $8.67 on June 26, 2026. Separately, Pomerantz LLP announced it is investigating potential securities fraud related to Omeros and certain officers/directors.

Analysis

This is less a litigation story than a financing story. For a single-program biotech, a negative European regulatory read-through cuts the probability-weighted value of the ex-US asset and, more importantly, shortens the runway to the next dilutive financing event if the company had been underwriting the story with future partnership economics.

The second-order effect is on negotiating leverage: any future licensing, royalty, or regional commercialization deal now clears at a lower upfront payment and worse contingent terms because counterparties will price in regulatory overhang and a narrower approval map. The lawsuit headline matters mainly if it surfaces disclosure gaps; absent that, the legal process is an overhang, not the primary driver of enterprise value.

The stock can still bounce mechanically after a 20% drawdown, but the next real catalyst is management guidance on cash burn, timeline, and whether the U.S. path remains intact. Over the next 1-3 months, the market will trade runway and dilution risk; over 6-18 months, this starts to behave like a stub option on one remaining regulatory pathway. The contrarian view is that some of the bad news is already in the price, so chasing the short after the gap-down is lower quality than waiting for a failed relief rally or a financing update that confirms the balance-sheet strain.

Key Decisions for Investors

• Avoid initiating fresh long OMER exposure until management quantifies cash runway and next regulatory steps; if already long, trim on any relief rally toward the prior support zone around $9.50-$10.00.
• Short OMER only on a failed bounce back above the 10-day moving average, with a tight cover trigger on any announcement of non-dilutive financing, partner support, or a materially stronger U.S. regulatory path.
• If you need biotech beta rather than idiosyncratic risk, prefer a pair trade: long IBB/XBI vs short OMER to isolate company-specific regulatory and dilution risk.
• Watch for a post-event financing filing or guidance revision over the next 30-60 days; a lower cash runway estimate is the clearest falsifier for any 'oversold' thesis and would justify pressing shorts.
• Use options cautiously only after implied volatility cools; if volatility stays elevated, a put spread on a bounce is better risk/reward than chasing common stock short at the current level.